Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $66,157.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 5,089 shares of the business’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $13.00, for a total value of $66,157.00. Following the completion of the sale, the chief financial officer directly owned 132,898 shares in the company, valued at $1,727,674. This trade represents a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Kory James Wentworth also recently made the following trade(s):

• On Tuesday, March 10th, Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.02, for a total value of $148,271.76.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The stock was sold at an average price of $12.25, for a total value of $97,853.00.

Entrada Therapeutics Stock Performance

Shares of TRDA stock opened at $12.69 on Friday. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $13.65. The company’s 50-day moving average is $11.34 and its 200 day moving average is $8.94. The company has a market capitalization of $485.77 million, a price-to-earnings ratio of -3.67 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.38. The business had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. As a group, research analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Institutional Trading of Entrada Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Baker BROS. Advisors LP raised its stake in shares of Entrada Therapeutics by 4.3% in the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after buying an additional 206,911 shares during the period. Wellington Management Group LLP grew its stake in shares of Entrada Therapeutics by 9.5% during the 4th quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock valued at $10,740,000 after acquiring an additional 90,339 shares during the period. Millennium Management LLC increased its holdings in Entrada Therapeutics by 391.2% in the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after acquiring an additional 666,287 shares in the last quarter. Geode Capital Management LLC increased its holdings in Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after acquiring an additional 42,479 shares in the last quarter. Finally, State Street Corp raised its stake in Entrada Therapeutics by 2.0% during the 4th quarter. State Street Corp now owns 508,789 shares of the company’s stock worth $5,230,000 after acquiring an additional 10,174 shares during the period. Institutional investors own 86.39% of the company’s stock.

Analyst Upgrades and Downgrades

TRDA has been the topic of several analyst reports. Wall Street Zen raised Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Oppenheimer initiated coverage on Entrada Therapeutics in a report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Monday, December 29th. Finally, Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.